Scholarlink

Background <p>To manage tick infestations and reduce tick-borne pathogen transmission risk to dogs, compliant administration of a fast-acting ectoparasiticide is necessary. Isoxazoline-containing ectoparasiticide products provide systemic whole-body coverage; however, differences in tick kill have been observed between products and these differences may be more pronounced when controlling common dose-limiting tick species such as <i>Amblyomma americanum</i>.</p> Methods <p>Dogs were ranked by tick carrying capacity, randomly allocated to one of three treatment groups, and administered Bravecto® Chews (minimum 25&#xa0;mg/kg fluralaner), Simparica TRIO® (minimum 1.2&#xa0;mg/kg sarolaner, 24&#xa0;µg/kg moxidectin, 5&#xa0;mg/kg pyrantel), or no treatment. Dogs were infested with approximately 50 unfed adult (25 female, 25 male) <i>A.&#xa0;americanum</i> on days −2, 21, 28, and 35. Live tick counts were performed at 8, 12, 24, 48, and 72&#xa0;h post-treatment (day 0) and post-infestation on days 21, 28, and 35. At each tick count timepoint, product efficacy was determined by comparing geometric mean live tick counts for each product-treated group to the untreated group and a linear mixed model was used for between-group comparisons.</p> Results <p>Compared with untreated dogs, significant control of existing <i>A.&#xa0;americanum</i> infestations began by 8&#xa0;h post-treatment (81.6%) and reached 98.0% control by 12-h for Bravecto®-treated dogs. In comparison, significant control for Simparica TRIO®-treated dogs began by 24&#xa0;h post-treatment (97.7%). When reinfested on day 21, <i>A.&#xa0;americanum</i> infestations were controlled more quickly for Bravecto® compared with Simparica TRIO®-treated dogs at 12&#xa0;h (efficacy 95.3% versus 25.5%, <i>P &lt; </i>0.001) and 24&#xa0;h (efficacy 99.7% versus 70.9%, <i>P</i> &lt; 0.001) post-infestation. Similarly, when reinfested on day 28, faster <i>A.&#xa0;americanum</i> control occurred for Bravecto® compared with Simparica TRIO®-treated dogs at 12&#xa0;h (efficacy 87.9% versus 18.3%, <i>P</i> &lt; 0.001) and at 24&#xa0;h (99.2% versus 59.3%, <i>P</i> &lt; 0.001) post-infestation. Finally, when reinfested on day 35, time to ≥ 90% efficacy was achieved by 48&#xa0;h for Bravecto®-treated dogs compared with 72&#xa0;h post-infestation for Simparica TRIO®-treated dogs. Both products performed within label indications and no treatment-related adverse reactions occurred during the study.</p> Conclusions <p><i>Amblyomma americanum</i> infestations are controlled more quickly immediately upon treatment and at 21, 28, and 35&#xa0;days post-treatment for Bravecto® compared with Simparica TRIO®-treated dogs.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of the initial and residual speed of Amblyomma americanum kill on dogs treated with a single dose of Bravecto® Chew (25 mg/kg fluralaner) or Simparica TRIO® (1.2 mg/kg sarolaner, 24 µg/kg moxidectin, 5 mg/kg pyrantel)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月21日

查看全文
  • Kathryn E. Reif,
  • Michael W. Dryden,
  • Dorothy M. Normile,
  • Qing Kang,
  • Brian H. Herrin,
  • Jeba R. J. Jesudoss Chelladurai,
  • Naemi P. Bickmeier,
  • Cameron J. Sutherland,
  • Mallory S. Beltz

摘要

Background

To manage tick infestations and reduce tick-borne pathogen transmission risk to dogs, compliant administration of a fast-acting ectoparasiticide is necessary. Isoxazoline-containing ectoparasiticide products provide systemic whole-body coverage; however, differences in tick kill have been observed between products and these differences may be more pronounced when controlling common dose-limiting tick species such as Amblyomma americanum.

Methods

Dogs were ranked by tick carrying capacity, randomly allocated to one of three treatment groups, and administered Bravecto® Chews (minimum 25 mg/kg fluralaner), Simparica TRIO® (minimum 1.2 mg/kg sarolaner, 24 µg/kg moxidectin, 5 mg/kg pyrantel), or no treatment. Dogs were infested with approximately 50 unfed adult (25 female, 25 male) A. americanum on days −2, 21, 28, and 35. Live tick counts were performed at 8, 12, 24, 48, and 72 h post-treatment (day 0) and post-infestation on days 21, 28, and 35. At each tick count timepoint, product efficacy was determined by comparing geometric mean live tick counts for each product-treated group to the untreated group and a linear mixed model was used for between-group comparisons.

Results

Compared with untreated dogs, significant control of existing A. americanum infestations began by 8 h post-treatment (81.6%) and reached 98.0% control by 12-h for Bravecto®-treated dogs. In comparison, significant control for Simparica TRIO®-treated dogs began by 24 h post-treatment (97.7%). When reinfested on day 21, A. americanum infestations were controlled more quickly for Bravecto® compared with Simparica TRIO®-treated dogs at 12 h (efficacy 95.3% versus 25.5%, P < 0.001) and 24 h (efficacy 99.7% versus 70.9%, P < 0.001) post-infestation. Similarly, when reinfested on day 28, faster A. americanum control occurred for Bravecto® compared with Simparica TRIO®-treated dogs at 12 h (efficacy 87.9% versus 18.3%, P < 0.001) and at 24 h (99.2% versus 59.3%, P < 0.001) post-infestation. Finally, when reinfested on day 35, time to ≥ 90% efficacy was achieved by 48 h for Bravecto®-treated dogs compared with 72 h post-infestation for Simparica TRIO®-treated dogs. Both products performed within label indications and no treatment-related adverse reactions occurred during the study.

Conclusions

Amblyomma americanum infestations are controlled more quickly immediately upon treatment and at 21, 28, and 35 days post-treatment for Bravecto® compared with Simparica TRIO®-treated dogs.

Graphical Abstract